BCL-xL heterobifunctional degrader (Zentalis Pharmaceuticals)

N/A

Report date: 2025/03/18 18:11:20
NME

Base Information

Drug NameBCL-xL heterobifunctional degrader (Zentalis Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-X inhibitors
TargetsApoptosis regulator Bcl-X
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZentalis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesZentalis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A